Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxaliplatin | DNA cross-linker | DNA cross-linker | 3.2681 | 4.9333 | 12.0662 | -0.9391 | -0.8084 | -0.7104 | -1.0000 | -1.0000 | -0.9516 | 0.6228 | 0.7486 | 1.0057 | 0.4005 | 0.5419 | 0.5768 | 14.7918 | 22.6957 | 42.6124 | |
| Erlotinib | EGFR | ErbB | 6.4716 | 35.2468 | 100.0000 | 0.0317 | 0.4006 | 0.6354 | -0.8374 | -0.1704 | 0.3788 | 0.3155 | 0.7139 | 1.8126 | 0.0351 | 0.1228 | 0.2396 | 13.2839 | 41.2968 | 100.0000 | |
| Nelfinavir | N/A | N/A | 8.4034 | 9.7440 | 15.4339 | -0.8211 | -0.6445 | -0.2989 | -1.0000 | -1.0000 | -0.8006 | 1.6805 | 2.3548 | 2.7767 | 0.1130 | 0.1589 | 0.1970 | 12.4011 | 15.3815 | 22.7642 | |
| Trichostatin A | HDAC | HDAC | 6.5374 | 11.5225 | 17.5553 | -0.9202 | -0.8512 | -0.7541 | -0.9053 | -0.8178 | -0.6756 | 1.3647 | 1.8955 | 2.2777 | 0.6490 | 0.7724 | 0.9158 | 11.0302 | 20.2024 | 30.2620 | |
| Gefitinib | EGFR | ErbB | 6.6704 | 12.9191 | 28.3915 | -0.2671 | 0.0424 | 0.3018 | -0.8465 | -0.5620 | -0.2259 | 0.9170 | 1.3719 | 2.5436 | 0.0767 | 0.1382 | 0.2408 | 9.0805 | 26.2291 | 41.5832 | |
| Cisplatin | DNA cross-linker | DNA cross-linker | 4.4823 | 11.6380 | 25.2438 | -0.8850 | -0.6449 | -0.2565 | -0.9047 | -0.5931 | -0.2921 | 1.0217 | 1.3698 | 2.2177 | 0.2715 | 0.3752 | 0.4391 | 8.7984 | 21.1543 | 38.4325 | |
| PD173074 | FGFR1/3 | RTK | 7.0478 | 8.9285 | 13.6750 | -0.8719 | -0.6669 | -0.2130 | -1.0000 | -0.9488 | -0.5559 | 1.6563 | 2.2671 | 4.5022 | 0.0991 | 0.1926 | 0.2504 | 8.7381 | 13.6708 | 21.0369 | |
| AG1024 | IGF1R | RTK | 14.2327 | 62.8199 | 100.0000 | 0.3069 | 0.5828 | 0.8614 | -0.0340 | 0.2904 | 0.6353 | 0.3280 | 1.4424 | 3.0172 | 0.0186 | 0.0785 | 0.1208 | 8.3409 | 30.1991 | 100.0000 | |
| Sunitinib | PDGFR/VEGFR/KIT/FLT3 | RTK | 4.8478 | 6.2817 | 9.9436 | -0.9902 | -0.9623 | -0.8818 | -0.9966 | -0.9683 | -0.8864 | 1.4527 | 2.4005 | 3.5359 | 0.3679 | 0.4354 | 0.4695 | 8.0047 | 9.6271 | 12.8243 | |
| CPT-11 | TOP1 | TOP | 3.1544 | 10.7270 | 20.8553 | -0.5980 | -0.2192 | 0.1666 | -0.9688 | -0.6234 | -0.1292 | 0.8799 | 1.3528 | 1.8883 | 0.1220 | 0.2195 | 0.2928 | 7.3583 | 23.7091 | 36.8667 | |
| AS-252424 | PI3K | PI3K | 19.5544 | 36.2256 | 100.0000 | 0.2865 | 0.4240 | 0.5918 | -0.9991 | 0.2157 | 0.5619 | 0.3148 | 0.6846 | 2.7243 | 0.0770 | 0.1059 | 0.1601 | 6.6689 | 89.5846 | 100.0000 | |
| Temsirolimus | MTOR | MTOR | 0.1192 | 1.7003 | 10.0307 | -0.9332 | -0.8176 | -0.6679 | -1.0000 | -1.0000 | -0.9967 | 0.2520 | 0.4363 | 1.0813 | 0.3951 | 0.4933 | 0.6311 | 6.4751 | 18.8586 | 43.0334 | |
| Sigma A6730 | AKT | AKT | 2.0327 | 6.5660 | 11.2198 | -0.9178 | -0.8320 | -0.6777 | -1.0000 | -1.0000 | -0.9546 | 0.9310 | 1.3794 | 2.0044 | 0.2439 | 0.2875 | 0.4042 | 6.3004 | 13.6236 | 19.0461 | |
| Olomoucine II | CDK1 | CDK | 3.7444 | 6.0358 | 7.3956 | -0.7023 | -0.3927 | -0.1441 | -0.7230 | -0.4357 | -0.1137 | 1.4260 | 2.7083 | 4.7257 | 0.2563 | 0.3202 | 0.3981 | 5.9885 | 7.0813 | 8.6384 | |
| Tozasertib | AURK/FLT3/ABL/JAK2 | AURK | 0.9523 | 4.3787 | 11.8540 | -0.5661 | -0.3376 | -0.0359 | -1.0000 | -1.0000 | -0.4350 | 0.4858 | 0.8218 | 1.3502 | 0.1794 | 0.3014 | 0.3656 | 4.7346 | 16.5294 | 34.8041 | |
| Etoposide | TOP2 | TOP | 1.1610 | 2.9708 | 7.6285 | -0.6938 | -0.4841 | -0.2079 | -0.7406 | -0.5842 | -0.4690 | 0.5531 | 0.8108 | 1.2247 | 0.3770 | 0.4769 | 0.5711 | 4.4274 | 7.6731 | 19.6965 | |
| Cetuximab | EGFR | ErbB | 100.0000 | 100.0000 | 100.0000 | 0.7284 | 0.8755 | 0.9754 | 0.5964 | 0.8555 | 0.9754 | 0.0000 | 0.0000 | 0.7916 | -0.0099 | 0.0234 | 0.0674 | 3.7461 | 100.0000 | 100.0000 | |
| AG1478 | EGFR | ErbB | 8.7673 | 51.6075 | 100.0000 | -0.0710 | 0.2684 | 0.6341 | -0.3109 | -0.0273 | 0.4206 | 0.8939 | 1.7205 | 2.6373 | 0.0902 | 0.1531 | 0.2936 | 3.7212 | 36.6666 | 94.4655 | |
| GSK1070916 | AURK | AURK | 0.6046 | 3.0981 | 6.6549 | -0.8474 | -0.6391 | -0.3610 | -1.0000 | -1.0000 | -0.9999 | 0.6499 | 0.9902 | 1.5949 | 0.2113 | 0.2924 | 0.4314 | 3.5405 | 8.2453 | 15.6107 | |
| IKK16 | IKK | NFKB | 1.8767 | 3.1049 | 3.8519 | -0.9668 | -0.9445 | -0.8619 | -0.9890 | -0.9578 | -0.8641 | 2.2018 | 3.4729 | 4.3592 | 0.3739 | 0.4332 | 0.4763 | 3.1521 | 4.0389 | 4.8853 | |
| GSK1838705A | IGF1R | RTK | 4.0665 | 10.9435 | 23.1329 | -0.6969 | -0.3849 | -0.1067 | -0.7773 | -0.4275 | -0.2150 | 1.5275 | 2.6721 | 3.2208 | 0.2264 | 0.2964 | 0.4149 | 2.6121 | 7.6760 | 17.5013 | |
| TPCA-1 | IKK | NFKB | 4.9121 | 23.5816 | 100.0000 | 0.0988 | 0.4346 | 0.6277 | -0.1071 | 0.3912 | 0.5674 | 0.5796 | 1.2158 | 2.2892 | 0.0966 | 0.1616 | 0.2244 | 2.5700 | 5.7466 | 43.2238 | |
| Glycyl-H-1152 | ROCK2 | N/A | 7.8389 | 29.5632 | 100.0000 | 0.0725 | 0.4318 | 0.6407 | -0.4259 | 0.0666 | 0.6245 | 0.3449 | 0.9010 | 2.0476 | 0.0704 | 0.1476 | 0.1891 | 2.5420 | 16.8696 | 100.0000 | |
| NSC 663284 | CDC25 | CDC | 1.6689 | 2.2519 | 3.0742 | -0.9668 | -0.9336 | -0.8607 | -0.9846 | -0.9413 | -0.8554 | 1.8405 | 2.5456 | 4.2988 | 0.5484 | 0.5805 | 0.6318 | 2.2603 | 3.4718 | 5.7633 | |
| Bosutinib | Src | nRTK | 1.2187 | 1.7497 | 4.1420 | -0.6727 | -0.4219 | -0.1512 | -0.7662 | -0.4684 | -0.1288 | 0.9612 | 1.6575 | 1.9534 | 0.3079 | 0.3819 | 0.4639 | 1.7722 | 2.5602 | 5.3523 |